Plus Therapeutics Inc
PSTV
Company Profile
Business description
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).
Contact
2710 Reed Road
Suite 160
HoustonTX77051
USAT: +1 737 255-7194
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
21
Stocks News & Analysis
stocks
Tesla’s stock is in trouble, but this fund manager sees a comeback in 2026
Tesla’s challenges echo past issues the company has overcome, says Zevenbergen’s Joe Dennison.
stocks
Cheap ASX energy play boasts strong cash flows and balance sheet
Markets appear overly bearish on the company despite the company having attracting growth options.
stocks
Market overreacts to earnings miss from moated ASX retailer
Our forecast recovery is off to a slow start but the sell-off appears to have gone too far.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,215.30 | 24.70 | -0.27% |
| CAC 40 | 7,843.04 | 126.65 | -1.59% |
| DAX 40 | 24,273.12 | 89.97 | -0.37% |
| Dow JONES (US) | 45,282.47 | 349.27 | -0.77% |
| FTSE 100 | 9,321.40 | 12.20 | 0.13% |
| HKSE | 25,750.88 | 79.03 | -0.31% |
| NASDAQ | 21,449.29 | 47.24 | -0.22% |
| Nikkei 225 | 42,354.53 | 453.29 | -1.06% |
| NZX 50 Index | 13,080.06 | 0.56 | 0.00% |
| S&P 500 | 6,439.32 | 27.59 | -0.43% |
| S&P/ASX 200 | 8,948.60 | 18.30 | -0.20% |
| SSE Composite Index | 3,871.35 | 12.21 | -0.31% |